cancer, including radical prostatectomy with or without pelvic lymph node dissection, external-beam radiation therapy (EBRT) with 4 to 6 months of androgen deprivation therapy (ADT), or combination EBRT with a brachytherapy (BT) boost with or without ADT
Search Results
Neal Andruska, Benjamin W. Fischer-Valuck, Ruben Carmona, Temitope Agabalogun, Randall J. Brenneman, Hiram A. Gay, Jeff M. Michalski, and Brian C. Baumann
Michelle T. Ashworth and Adil Daud
chest, abdomen, and pelvis identified no other lesions, and results of a complete right inguinal lymph node dissection were negative. The patient was treated with adjuvant radiotherapy (XRT), complicated by a nonhealing ulcer for 1 year and persistent
Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse
omental caking. CA-125 serum tumor marker at time of presentation was elevated at 1,155 kU/L (normal range, <35 kU/L). The patient underwent primary surgery with radical hysterectomy, bilateral salpingo-oophorectomy, lymph node dissection, and removal of
Saranya Chumsri, Ethan S. Sokol, Aixa E. Soyano-Muller, Ricardo D. Parrondo, Gina A. Reynolds, Aziza Nassar, and E. Aubrey Thompson
subsequently underwent right modified radical mastectomy with axillary lymph node dissection. Pathology results showed multifocal residual disease measuring up to 16.5 cm, with >10 additional satellite tumors and skin involvement. Among resected axillary lymph
Aysegul A. Sahin, Timothy D. Gilligan, and Jimmy J. Caudell
with retroperitoneal lymph node dissection only? Which patients with stage II and III disease will need to undergo resection of residual masses after chemotherapy?” he continued. Dr. Gilligan explained that the 8th edition has made some changes, but
James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Bruce J. Roth, Dennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski, and Patrick C. Walsh
decision-making for men contemplating active surveillance, 12 radical prostatectomy, 13 – 15 neurovascular bundle preservation, 16 – 18 or omission of pelvic lymph node dissection (PLND) during radical prostatectomy, 19 brachytherapy, 13 , 20 , 21 or
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars
pregnant during breast cancer treatment (see page 160). Locoregional Treatment Several randomized trials document that mastectomy with axillary lymph node dissection is equivalent to breast-conserving therapy with lumpectomy, axillary dissection
Lyndsay J. Willmott, Daniele A. Sumner, and Bradley J. Monk
treatment protocol is surgical resection, typically with radical hysterectomy and pelvic lymph node dissection. Cure rates are good in this instance. However, more advanced disease is a greater challenge to treat effectively. The American Cancer Society
Andrea Maurichi, Rosalba Miceli, Roberto Patuzzo, Francesco Barretta, Gianfranco Gallino, Ilaria Mattavelli, Consuelo Barbieri, Andrea Leva, Umberto Cortinovis, Elena Tolomio, Milena Sant, Gianpiero Castelli, Leonardo Zichichi, Giovanni Pellacani, Ignazio Stanganelli, Marco Simonacci, Ausilia Manganoni, Corrado Del Forno, Gioachino Caresana, Catherine Harwood, Daniele Bergamaschi, Konstantinos Lasithiotakis, Dorothy Bennett, Vittoria Espeli, Cristina Mangas, Sandra Leoni Parvex, Barbara Valeri, Mara Cossa, Marta Barisella, Alessandro Pellegrinelli, Claudia Miranda, Andrea Anichini, Roberta Mortarini, Odysseas Zoras, and Mario Santinami
completion lymph node dissection (CLND) as additional therapy. Statistical Methods Clinicopathologic characteristics were recorded according to SNB (performed vs not performed) for the whole series of patients, according to SN status (positive vs negative) in
David J. Worhunsky, Yifei Ma, Yulia Zak, George A. Poultsides, Jeffrey A. Norton, Kim F. Rhoads, and Brendan C. Visser
Although multiple quality indicators have been studied for the management of gastric cancer, notably surgical technique and the extent of lymph node dissection, 12 – 14 limited data exist regarding implementation and effectiveness of clinical guidelines
